← Back to all studies
anti-inflammatory foods

Unravelling Sarcopenia in Chronic Kidney Disease: From Pathogenesis to Diagnosis and Therapeutics

1 April 2026

Vallianou NG, Evangelopoulos AA, Christodoulatos GS, Tantsi I, Mantouvalos N, Chatzis D, Stratigou T, Geladari EV, Constantinou K, Tousis A, Kounatidis DC.

Summary

Plain-Language Summary This research highlights that 25% of people with Chronic Kidney Disease (CKD) suffer from sarcopenia—the debilitating loss of muscle mass and strength. The study explains that muscle wasting in CKD is caused by a complex "perfect storm" of systemic inflammation, toxins, and poor nutrition, emphasizing that maintaining muscle is vital for longevity and quality of life.

Key Findings

  • Multifactorial Causes: Muscle loss isn't just about aging; it is driven by uremic toxins, gut health imbalances (dysbiosis), and chronic inflammation from related issues like diabetes and heart disease.
  • The Gut-Muscle Axis: Poor gut health contributes to systemic inflammation, which directly accelerates muscle atrophy.
  • Vitamin D Deficiency: Low vitamin D levels are a significant, treatable driver of muscle weakness in kidney patients.
  • Environmental Impact: External factors, including air pollution, are emerging as surprising contributors to the progression of sarcopenia.

Practical Takeaways

  • Move Regularly: Physical activity remains the most effective "cornerstone" for delaying muscle loss and maintaining metabolic health.
  • Optimize Micronutrients: Focus on correcting Vitamin D deficiencies and ensuring adequate mineral intake to protect skeletal muscle.
  • Target Inflammation: Use an anti-inflammatory approach to diet and lifestyle to reduce the "low-grade inflammation" that triggers muscle breakdown.
  • Prioritize Gut Health: Support your microbiome through fiber and fermented foods to help reduce the toxic load on the kidneys.

Study Limitations As a literature review, this study synthesizes existing research rather than providing new clinical data. Additionally, some discussed drug therapies remain in the experimental stage and are not yet available for general use.

Word Count: 265 words

Abstract

Chronic kidney disease (CKD) is on the rise, with sarcopenia accompanying CKD in an estimated 25% of patients, featuring as a potentially debilitating issue that should not be overlooked. Sarcopenia, characterized by a loss of skeletal muscle mass and strength, is multifactorial. The aging process, uremic toxins, systemic inflammation, oxidative stress, gut dysbiosis, hormonal dysregulation, dietary deficits, and even air pollution are among the major parameters being implicated in sarcopenia among patients with CKD. Additionally, the existence of various comorbidities, such as type 2 diabetes mellitus (T2DM), depression, and cardiovascular diseases (CVD), also contribute to the chronic low-grade inflammation associated with skeletal muscle inflammation and atrophy. The purpose of this review is to delve into the complex interplay of multiple factors being involved in the pathogenesis of sarcopenia in patients with CKD. Moreover, we aim to shed light upon nutritional aspects that could delay the development and progression of sarcopenia among patients with CKD. To address vitamin D deficiency, micronutrients and macronutrients together with physical activity remain the cornerstone of delaying the progression of sarcopenia in this sub-population. Additionally, experimental drugs exhibiting therapeutic potential are also being discussed. As sarcopenia and quality of life are interconnected, the timely recognition of sarcopenia, together with nutritional and therapeutic interventions, is of the utmost importance in our crusade for a better quality of life (QoL) in patients with CKD.
Source study →